Table 3.
Demographic, clinical and serological data of the SCIT-treated study group and the control cohort - with allergy to HDM.
| Characteristics | Study group treated by SCIT with HDM (n = 14) | Control group without SCIT with HDM (n = 6) |
|---|---|---|
| Gender | ||
| Male | 10 (71%) | 5 (83%) |
| Female | 4 (29%) | 1 (17%) |
| Age (yrs) | 23 (range: 6–44) | 14 (range: 6–24) |
| Children <12 years old | 4 (29%) | 2 (33%) |
| Number of allergen sources sensitized to | 2.8 | 2.8 |
| Most common co-sensitization against | ||
| Poaceae | 8 (57%) | 3 (50%) |
| Fagales | 7 (50%) | 1 (17%) |
| Cat | 3 (21%) | 1 (17%) |
| Oleaceae | 2 (14%) | 1 (17%) |
| OAS related to various allergen sources | 3 (21%) | 1 (17%) |
| Asthmatic complaints | 4 (29%) | 0 (0%) |
| Atopic dermatitis | 1 (7%) | 0 (0%) |
| Total serum IgE [kU/l] | 222 (range: 8–2103) | 217 (range: 17–470) |
| Prevalence of sIgE, prior to therapy, against | ||
| Der p 1 | 12 (86%) | 4 (67%) |
| Der p 2 | 12 (86%) | 5 (83%) |
| Der p 23 | 10 (71%) | 5 (83%) |
| Der p 5 | 5 (36%) | 1 (17%) |
| Der p 7 | 4 (29%) | 2 (33%) |
| Der p 10 | 2 (14%) | 0 (0%) |
| Der p 11 | 2 (14%) | 0 (0%) |
Age is given as mean and range, number of allergen sources sensitized to is given as mean and and total serum IgE is given as median and range. All other values are number of patients total and percent of each evaluated subgroup.
Many parameters were comparable in the SCIT-treated study group and the control cohort.